Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 S372C |
| Therapy | Lenvatinib |
| Indication/Tumor Type | cholangiocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 S372C | cholangiocarcinoma | predicted - sensitive | Lenvatinib | Case Reports/Case Series | Actionable | In a clinical case study, Lenvima (lenvatinib) treatment resulted in a partial response in a patient with cholangiocarcinoma harboring FGFR2 S372C (PMID: 38346946). | 38346946 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38346946) | The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma. | Full reference... |